RESEARCH



Open Access

Stimulation of ovarian stem cells by follicle stimulating hormone and basic fibroblast growth factor during cortical tissue culture

Seema Parte¹, Deepa Bhartiya^{1*}, Dhananjay D Manjramkar², Anahita Chauhan³ and Amita Joshi⁴

Abstract

Background: Cryopreserved ovarian cortical tissue acts as a source of primordial follicles (PF) which can either be auto-transplanted or cultured *in vitro* to obtain mature oocytes. This offers a good opportunity to attain biological parenthood to individuals with gonadal insufficiency including cancer survivors. However, role of various intra- and extra-ovarian factors during PF growth initiation still remain poorly understood. Ovarian biology has assumed a different dimension due to emerging data on presence of pluripotent very small embryonic-like stem cells (VSELs) and ovarian germ stem cells (OGSCs) in ovary surface epithelium (OSE) and the concept of postnatal oogenesis. The present study was undertaken to decipher effect of follicle stimulating hormone (FSH) and basic fibroblast growth factor (bFGF) on the growth initiation of PF during organ culture with a focus on ovarian stem cells.

Methods: Serum-free cultures of marmoset (n=3) and human (young and peri-menopausal) ovarian cortical tissue pieces were established. Cortical tissue pieces stimulated with FSH (0.5 IU/ml) or bFGF (100 ng/ml) were collected on Day 3 for histological and molecular studies. Gene transcripts specific for pluripotency (Oct-4A, Nanog), early germ cells (Oct-4, c-Kit, Vasa) and to reflect PF growth initiation (oocyte-specific Gdf-9 and Lhx8, and granulosa cells specific Amh) were studied by q-RTPCR.

Results: A prominent proliferation of OSE (which harbors stem cells) and transition of PF to primary follicles was observed after FSH and bFGF treatment. Ovarian stem cells were found to be released on the culture inserts and retained the potential to spontaneously differentiate into oocyte-like structures in extended cultures. q-RTPCR analysis revealed an increased expression of gene transcripts specific for VSELs, OGSCs and early germ cells suggestive of follicular transition.

Conclusion: The present study shows that both FSH and bFGF stimulate stem cells present in OSE and also lead to PF growth initiation. Thus besides being a source of PF, cryopreserved ovarian cortical tissue could also be a source of stem cells which retain the ability to spontaneously differentiate into oocyte-like structures *in vitro*. Results provide a paradigm shift in the basic understanding of FSH action and also offer a new perspective to the field of oncofertility research.

Keywords: Primordial follicles, Organ culture, Germ cells, Ovarian stem cells, VSELs

Background

Culture of ovarian cortical tissue is carried out to allow the transition of resting phase primordial follicles (PF) to primary and secondary follicular stage. This is an interesting *in vitro* system to investigate the basic mechanisms involved in the activation and development of PF. This approach has also been implicated as a possible option to

achieve biological parenthood in women cancer survivors and cryopreservation of ovarian cortical tissue is currently performed prior to cancer treatment for preservation of their fertility [1-4]. Currently, the practiced strategy involves auto-transplantation of cryopreserved ovarian tissue post cancer treatment. But, this may pose a high risk of reintroducing cancer in spite of remission from disease. Hence in the context of fertility preservation, *in vitro* maturation of PF from cryopreserved tissue is an excellent option for such females and also for those who wish to delay pregnancy for career or other reasons.



© 2013 Parte et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

^{*} Correspondence: bhartiyad@nirrh.res.in

¹Stem Cell Biology Department, National Institute for Research in Reproductive Health (NIRRH), JM Street, Parel, Mumbai 400 012, India Full list of author information is available at the end of the article

Ovarian cortical tissue culture however, cannot support follicle development of all stages, as the concentration and optimal timing of nutrient/growth factor requirements is stage-specific and not yet deciphered completely. Hence, a two-step procedure for follicular maturation has been proposed. The first stage involves serum-free culture of cortical tissue for 3-6 days, wherein the PF transitions to primary and secondary stage. This would be followed by *in vitro* maturation of cumulus-oocyte-complexes [2,3]. Recently, 3D culture of follicles for maturation of the oocytes has also shown promising results [5].

Till date, many intra- and extra-ovarian factors reguired for PF activation and follicle development in organ cultures have been studied. Role of follicle stimulating hormone (FSH), an extra-ovarian factor, during PF transition remains controversial. It has emerged as a survival factor [6] however the mechanisms underlying FSH action are not clear. PF growth is considered to be independent of FSH action as they (PF) lack FSH receptors [7,8]. Silva et al [9] reported that PF get activated spontaneously in caprine ovarian tissue culture and do not require FSH or EGF. Although both FSH and EGF stimulated an increase in oocyte and follicle size in intermediate and primary follicles in 5 days culture, no effect on proliferation or viability of follicles was observed in response to the treatment. Recently it has been suggested that FSH might act indirectly on the PF through paracrine factors secreted by large follicles or stromal cells [10]. This argument however remains unclear since FSH acts as a survival factor despite absence of large follicles in the cortical tissue pieces. Thus, more careful studies are necessary to understand the role of FSH as a survival factor.

Another important factor attributed to PF transition is basic fibroblast growth factor (bFGF). It is expressed in the ooplasm of primordial and primary follicles and also in the ovarian surface epithelium (OSE), smooth muscle cells surrounding blood vessels and corpus luteum [11]. Basic FGF when combined with FSH promoted PF survival and development in goats [12]. bFGF is also speculated to have a role in follicle recruitment and growth by stimulating granulosa cell proliferation [11]. Quennell et al [13] demonstrated the presence of bFGF transcripts in PF as well as decrease in its levels as the follicles grew in size. Garor et al [14] demonstrated the role of bFGF in human PF transition to primary follicles. Tang et al [15] reported that bFGF improved the effect of FSH on PF development and survival during long term culture of bovine ovarian tissue.

It was interesting to observe that FSH receptors and bFGF are expressed in the ovary surface epithelium [11,16] which also lodges ovarian stem cells [17-20]. Further bFGF is known to be a crucial component of culture medium required to maintain the pluripotency of human embryonic

stem cells [21-24]. This emerging understanding motivated us to undertake the present study to investigate the *in vitro* effect of FSH and bFGF on PF growth with a focus on ovarian stem cells in the ovarian cortical tissues of marmoset and human ovaries. Day 3 (D3) was chosen as the time point for various analyses in the present study, since available studies suggest that spontaneous activation of PF occurs within 2-3 days *in vitro* [25-28]. Histological and q-RTPCR analysis have been carried out for various stem cell, oocyte and granulosa cell specific markers (please refer to the Additional file 1: Table S1) to study the effect of FSH and bFGF on ovarian stem cells and PF growth *in vitro*.

Material and methods

Procurement of ovarian tissue

The study for the use of marmoset ovaries was approved by the Institute Animal Ethics Committee of National Institute for Research in Reproductive Health (NIRRH). Use of human ovarian tissue for research was approved by the Human Ethics Committee of NIRRH and King Edward Memorial (KEM) Hospital. Ovarian tissue was collected from marmosets (n=3; normal cycling young adults, 3 to 4 years of age) and women (n=2; one young ovarian sample from a postmortem case of a 13 years old girl collected 6-7 hrs after death and one adult ovary from a peri-menopausal woman undergoing total abdominal hysterectomy) for the study. The young ovarian sample was collected at the time of autopsy from the Surgical Pathology unit and the peri-menopausal ovarian sample was procured from the Obstetrics and Gynecology unit, KEM Hospital. All the culture studies and further analysis were carried out at NIRRH.

Ovarian cortical tissue culture

Ovarian tissue was transported in 0.9% normal salinecontaining antibiotics (penicillin 100 U/ml, streptomycin 100 µg/ml; Invitrogen, Carlsbad, CA, USA) at ambient temperature to the laboratory. It was gently rinsed several times in calcium and magnesium-free Dulbecco's phosphate-buffered saline (DPBS; Invitrogen) containing antibiotics. Ovarian cortical tissue (6-8 pieces of 1 mm³ size) were placed on 0.4 µm Millicell-CM inserts (Millipore, Bedford, MA, USA) fitted within six-well plates (NUNC, USA) and cultured at the interface between air and 1.1 ml of culture media, similar to that described previously [14]. The basal culture medium comprised of alpha-MEM (Invitrogen) containing 0.47 M ribonucleotides, 2 mM/L sodium pyruvate (Sigma-Aldrich, USA), 2 mM/L L-glutamine (Sigma-Aldrich), 1% insulin, transferrin, and selenium (Sigma-Aldrich), 0.05% Penicillin-Streptomycin (Invitrogen) and 2% human serum albumin (Sigma Aldrich). Ovarian tissues were treated with 0.5 IU/ ml human urinary FSH [Utrofol, Kuanart Pharmaceuticals,

Mumbai] and 100 ng/ml basic FGF [R & D Systems Inc, MN, USA]. Thus three different group of cultures were established including (A) untreated control (basal medium) (B) FSH treated [basal media supplemented with FSH], and (C) bFGF treated [basal media supplemented with bFGF]. Cultures were maintained in 5% CO₂ at 37°C and were monitored regularly under an inverted microscope with Hoffman optics (Eclipse TE2000-S; Nikon, Japan). The cortical tissue pieces were collected from the cell culture inserts after three days and processed for histology and RNA extraction. The peri-menopausal ovarian tissue was treated only with FSH due to sample limitations. Details of various studies undertaken are shown in Table 1. In addition, cells observed to be released from the cortical tissue on to the surface of the cell culture inserts, were further cultured and regularly monitored up to three weeks.

Histology of ovarian cortical tissue

Cortical tissue pieces collected were fixed in 10% neutral buffered formalin for 12 hours at 4°C and subsequently dehydrated in a series of alcohol grades and processed for paraffin embedding using standard protocols. 5 μ m thin sections were cut, stained with H & E and images of representative areas were captured using Nikon 90i Microscope (Nikon, Tokyo, Japan).

RNA extraction and q-RTPCR studies

Levels of transcripts for pluripotent stem cells (Oct-4A, Nanog), early germ cells/oocyte specific (Oct-4, c-Kit, Vasa) and to reflect PF transition into primary follicles

(oocyte-specific Gdf-9 and Lhx8, and granulosa cell specific Amh) were analyzed by q-RTPCR. Both total Oct-4 (comprising various isoforms) and Oct-4A (transcript specific for pluripotency) were studied to arrive at meaningful data showing the presence of VSELs and differentiated OGSCs respectively, as reported earlier [19].

Total RNA was extracted from the ovarian tissue pieces collected on D3 using standard TRIZOL (Invitrogen) method. RNA extraction method and cDNA preparation procedures were similar to those described earlier [19]. Real-time PCR analysis was performed using 2.5 μ L of cDNA and 10 pmol of gene specific primers (Table 2). The comparative threshold cycle (Ct) values were calculated using CFX 96 Real-Time PCR system (Bio-Rad Laboratories, CA, USA) using SYBR Green chemistry (Bio-Rad).

Amplification conditions comprised of an initial denaturation at 95°C for 3 min, followed by 45 cycles of denaturation at 94°C for 30s, annealing for 30s at respective temperature followed by elongation at 72°C for 50 sec. The melt curve analysis was performed at the end of 45 cycles to determine the homogeneity of the amplified products. The Ct values generated by CFX manager software (Bio-Rad) were normalized with respect to housekeeping gene 18S rRNA for all samples, and the Delta-Delta Ct values for each gene transcript were computed manually by subtracting delta Ct value of treated sample with that of its respective untreated control. Data obtained by q-RTPCR analysis using three adult marmosets, one each of young and peri-menopausal human ovarian samples are represented individually. All reactions

Table 1 Experiments performed on marmoset and human ovarian cortical tissue

Experiments undertaken	Details of ovary samples used in the study						
	Marmosets 1-3		Young human		Peri-menopausal human		
Organ culture	D3		D3		D3		
FSH group	\checkmark		\checkmark		\checkmark		
bFGF group	\checkmark		\checkmark		ND		
Histology	D3		D3		D3		
FSH group	\checkmark		\checkmark		\checkmark		
bFGF group	\checkmark		\checkmark		ND		
q-RTPCR	FSH	bFGF	FSH	bFGF	FSH	bFGF	
Oct-4A	\checkmark	\checkmark		\checkmark		ND	
Nanog	\checkmark	\checkmark		\checkmark	\checkmark	ND	
Oct-4	\checkmark	\checkmark		\checkmark	\checkmark	ND	
c-Kit	\checkmark	\checkmark		\checkmark		ND	
Vasa	\checkmark	\checkmark		\checkmark		ND	
Gdf-9	\checkmark	\checkmark		\checkmark	ND	ND	
Lhx8	\checkmark	\checkmark	\checkmark	\checkmark	ND	ND	
Amh		\checkmark	\checkmark	\checkmark	ND	ND	

 \checkmark : experiment done; ND: experiment not done.

Pluripotent markers (Human) Oct-4A F: AGCCCTCATITCACCAGGCC 57°C 448 R: TGGGACTCCTCCGGGTTITG 57°C 285 Nanog F: TGCAAATGTCTTCTGCTGAGAT 57°C 285 R: GTTCAGGATGTTGGAGAGTTC 57°C 285 R: GTTCAGGATGTTGGAGAGTTC 57°C 285 R: GTTCAGGATGTTGGAGAGTTC 57°C 285 Oct-4 F: GAAGGTATTCAGCACACGGG 55°C 315 R: GTTACAGAACCACACTCGGA 55°C 124 R: GTTACAGGAACCACACTCGGA 64°C 124 R: CCCCAGGGTGAGCCCCACAT 60°C 376 R: ATTGGTCACTTCTGGGTTG 60°C 376 R: ATTGGTCACTTCTGGGTTG 55°C 418 R: TTT GGC GCT GTT CCT TTG AT 60°C 202 R: CCACGGAGGAGGAGTGACCTG 60°C 202 R: CCACGGAGGAGGAAGTGACCTG 60°C 202 R: CCCAGGGAGGGAAGTGACCTGG 64°C 190 R: ACCAGGTAACACGAGGAGG 44% 190 R: ACCAGGTAACACGGGAGGTACAGGGA 62°C 230 R: GCCACGGAGGAGAGTACAGGGA 62°C 230 R: GCCACGTAGC	Gene	Primer sequence	Annealing temperature (°C)	Amplicon size (bp)
Oct-4AF: AGCCCTCATTTCACCAGGCC57°C448R: TGGGACTCCTCCGGGGTTTGNanogF: TGCAAATGTCTTCTGCTGAGAT57°C285R: GTTCAGGATGTTGAGAGTTCOct-4F: GAAGGTATTCAGCAAACGAC55°C315R: GTTACAGAACCACCCGGAOct-4 (marmoset)F: CCCCTGGTGCTGGAAGCTGG64°C124R: CCCCGGGTGGCCCCACATCct-4 (marmoset)F: CCCTGGGGTGGCCCCACATR: ATTGGTCACTTCTGGGTCTGVasaF: GAC TGC GGC TTT TCT CCT ACC55°C418R: TTT GGC GCT TT TCT CCT ACC55°C418R: TTT GGC GCT TT TCT CCT ACC55°C418R: TTT GGC GCT TT CT CT ACC55°C418R: TTT GGC GCT TT CT CT ACC55°C418R: TTT GGC GCT TT CT CT ACC55°C418R: TTT GGC GGT GT CCT TG ATPF transition markers (Human)AmhF: CACCTGGAGGAAGTGACCTG60°C202R: CACCGCTAACACCAGGTAG64°C190R: CCACGGTAGGTGACTGGGGA-GGAGGTGTCTCG291R: TGCACACACATTGCAGGAA62°C230R: GGACGGAGGCAGGATTAGC65°C291R: TGCACACACATTGCCAGGAA62°C230R: GGACGGAGGCAGGAATAAGC230R: GGACGGAGGCCGCAGAATAAGC230R: GGAAGGGAGCCTGAGAAACC60°C171B: CGCCGCAAATTGCCCCCCTTA171D: CCCCGCAATCACCTTA <td></td> <td>Pluripotent mark</td> <td>ers (Human)</td> <td></td>		Pluripotent mark	ers (Human)	
R: TGGGACTCCTCCGGGTTTTG 285 R: GTTCAGGATGTTGGAGAGTTC 285 R: GTTCAGGATGTTGGAGAGTTC 285 Early germ cell markers (Human) Oct-4 F: GAAGGTATTCAGCCAAACGAC 55°C 315 R: GTTACAGAACCACACTCGGA 55°C 315 R: GTTACAGAACCACACTCGGA 55°C 315 R: GTTACAGAACCACACTCGGA 64°C 124 R: GTTACAGGAGGTGGAGCCCCACAT 60°C 376 R: CCCCAGGGTGGAGCCCCACAT 60°C 376 R: ATTGGTCACTTCTGGGTTG 60°C 376 R: ATTGGTCACTTCTGGGTCTG 776 418 R: TTT GGC GCT GT TC CT ACC 55°C 418 R: TTT GGC GCT GT TC CT ACC 55°C 418 R: TTT GGC GCT GT TC CT ACC 55°C 202 R: TT GGC GCT GT CC T TG AT 70°C 202 R: CCACCGGAGAAGTGACCTG 60°C 202 R: CCACGGAGGAAGTGACCTG 60°C 202 R: CCACGGAGAGGAAGTGACATGG 62°C 291 R: CCACGGAGGTAGCAGGTAACAGGAAT 65°C 291 R: GCACACTAGCAATTTGACAGGAAAGC 230 R: GGCACGTAGGCAGAAAGGAAACC	Oct-4A	F: AGCCCTCATTTCACCAGGCC	57°C	448
NanogF. TGCAAATGTCTTCTGCTGAGAT57°C285R: GTTCAGGATGTTGGAGAGTTCEarly germ cell markers (Human)Oct-4F. GAAGGTATTCAGCCAAACGAC55°C315R: GTTACAGAACCACACTCGGAOct-4 (marmoset)F. CCCCTGGTGCTGTGAAGCTGG64°C124R: CCCCAGGGTGAGCCCCACATC-KitF. CCCTGGGTGTGTGAAGCTGG60°C376R: ATTGGTCACTTCTGGGTCTG60°C376WasaF. CCTGGGAGTTTC CCC ACC55°C418R: TTT GGC GCT GT TC CT ACC55°C418R: TTT GGC GCT GT TC CT ACC55°C202AmhF. CACCTGCAGGGAAGTGACCTG60°C202R: CCACCGCTAACACCAGGTAG60°C202R: CCACCGCTAACACCAGGTAGG100100R: CCACGGTAGGGAAGTGACCTG60°C202R: CCACGGTAGGAAGTGACCTG60°C202R: CCACGGTAGCAGGTAACAGGAAGT65°C291R: CCACGGTAGCAGGTAACAGGAAT65°C291R: TGCACACACATTTGACAGCAGGAAT65°C291R: TGCACACACATTTGACAGGAAGG2301185F: GGAGAGGCAGGCAGAAACAGGAAAC60°C171TasF: GGAGAGGGAGCCTGAGAAAC60°C171B: CCCCTGATGCCAGAAAC60°C171B: CCCCTGATGCAGCAAACC60°C171		R: TGGGACTCCTCCGGGTTTTG		
R: GTTCAGGATGTTGGAGAGTTC Early gern cell markers (Human) Oct-4 F: GAAGGTATTCAGCCAAACGAC 55°C 315 R: GTTACAGAACCACCTCGGA C 124 R: GTTACAGAACCACCACTGG 64°C 124 R: CCCCAGGGTGAGCCCCACAT C 376 R: CCCCAGGGTGAGCCCCACAT 60°C 376 R: ATTGGTCACTTCTGGGTCTG 60°C 376 Vasa F: GAC TGC GGC TIT TCT CCT ACC 55°C 418 R: TIT GGC GCT GTT CCT TIG AT 77 78 PF transition markers (Human) Amh F: CACCTGGAGGAAGTGACCTG 60°C 202 R: CCACGCTAACACCAGGTAG 60°C 202 R: CCACGGCTAACACCAGGTAG 60°C 202 R: CCACGGCTAACACCAGGTAG 60°C 202 R: CCACGGCTAACACCAGGTAGC 60°C 202 R: CCACGGCTAACACCAGGTAGC 60°C 202 R: CCACGGCTAACACCAGGTAAC 60°C 202 R: CCACGGCTAACACCAGGTAAC 60°C 202 R: CCACGGCTAACACCAGGTAACAGGAAT 65°C 291 R: ACCAGGTAGCAGGAACAGGGAACACGGGAACAC 64°C	Nanog	F: TGCAAATGTCTTCTGCTGAGAT	57°C	285
Early germ cell markers (Human) Oct-4 F: GAAGGTATTCAGCCAAACGAC 55°C 315 R: GTTACAGAACCACACTCGGA 64°C 124 R: GTTACAGAACCACACTCGGA 64°C 124 R: CCCCAGGGTGAGCCCCACAT 60°C 376 c-Kit F: CCTGGGATITTCTCTGCGTT 60°C 376 R: ATTGGTCACTTCTGGGTCTG 60°C 376 N: ATTGGTCACTTCTGGGTCTG 60°C 202 Vasa F: GAC TGC GGC TTT TCT CCT ACC 55°C 418 R: TTT GGC GCT GTT CCT TIG AT 7 7 PF transition markers (Human) Amh F: CACCTGGAGGAAGTGACCTG 60°C 202 R: CCACCGCTAACACCAGGTAG 60°C 202 R: CCACCGCTAGGAAGTGACATGG 60°C 202 R: CCACCGCTAGGAAGTGACATGG 60°C 202 R: ACCAGGTAGGGAGCTGAGCAAGG 7 190 R: ACCAGGTAGGCAAGTAACAGGAAT 65°C 291 R: GCACCAGCACAGTTGACAGGAAGG 62°C 230 R: GGCACGTAGGCAGAATAAGC 71 71 Housekeeping gene (Human) 185 F: GGAGAGG		R: GTTCAGGATGTTGGAGAGTTC		
Oct-4 F: GAAGGTATTCAGCCAAACGAC 55°C 315 R: GTTACAGAACCACCTCGGA S5°C 315 Oct-4 (marmoset) F: CCCCTGGTGCTGTGAAGCTGG 64°C 124 R: CCCCAGGGTGAGCCCCACAT 60°C 376 c-Kit F: CCCTGGGATTTCTCTGCGTT 60°C 376 R: ATTGGTCACTTCTGGGTCTG 60°C 418 R: TTT GGC GCT GTT TCT CCT ACC 55°C 418 R: TTT GGC GCT GTT CCT TIG AT 77 77 PF transition markers (Human) Amh F: CACCTGGAGGAAGTGACCTG 60°C 202 R: CCACCGCTAACACCAGGTAG 64°C 190 R: CCACCGGCTAACACCAGGTAG 64°C 190 R: ACCAGGTAGGGGAGTGACATGG 65°C 291 R: ACCAGGTAGTGGGTGTCTCG 65°C 291 R: ACCAGGTAGGAGCAGGTAACAGGAAT 65°C 291 R: TGCACACACTTTGACAGCAGGAGA 62°C 230 R: GGCACGTAGGCAGAATAAGGC 71 71 Housekeeping gene (Human) 18S F: GGAGAGGCAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGA		Early germ cell mai	rkers (Human)	
R: GTTACAGAACCACACTCGGA 124 Oct-4 (marmoset) F: CCCCTGGTGCTGTGAAGCCTGG 64°C 124 R: CCCCAGGGTGAGCCCCACAT 60°C 376 c-Kit F: CCTGGGATTTTCTCGGGTT 60°C 376 R: ATTGGTCACTTCTGGGTCTG 55°C 418 R: TTT GGC GCT GTT CCT ACC 55°C 418 R: TTT GGC GCT GTT CCT TG AT 7 7 PF transition markers (Human) Amh F: CACCTGGAGGAAGTGACCTG 60°C 202 R: CCACCGCTAACACCAGGTAG 60°C 202 R: CCACCGGCTAACACCAGGTAG 60°C 202 R: ACCAGGTAGGAGAGTGACCTG 60°C 202 R: CCACCGCTAACACACAGTAG 60°C 202 R: ACCAGGTAGGAGAGTGACATGG 64°C 190 R: ACCAGGTAGGGAGACCAGGTAACAGGAAT 65°C 291 R: TGCACACACATTTGACAGGAAGGG 190 185 F: CAAGCACAATTGCTCAGGA Housekeeping gene (Human) Housekeeping gene (Human)	Oct-4	F: GAAGGTATTCAGCCAAACGAC	55°C	315
Oct-4 (marmoset) F: CCCTGGTGCTGTGAAGCTGG 64°C 124 R: CCCAGGGTGAGCCCCACAT R: CCCCAGGGTGAGCCCCACAT 376 c-Kit F: CCTGGGATTTTCTCTGCGTT 60°C 376 R: ATTGGTCACTTCTGGGTCTG 60°C 418 R: TTT GGC GCT GTT CCT ACC 55°C 418 R: TTT GGC GCT GTT CCT TG AT 7 7 PF transition markers (Human) Amh F: CACCTGGAGGAAGTGACCTG 60°C 202 R: CCACGCTAACACCAGGTAG 64°C 190 R: CCACGGTAGGAGAGTGACATGG 64°C 190 R: CCACGGTAAGCAGGGAAGTGACATGG 65°C 291 R: ACCAGGTAGTGGGTGTCTCG 202 203 R: ACCAGGTAAGTGAGCAAGGAAAC 65°C 291 R: GCCACCACATTTGACAGCAGAGAG 203 203 R: GGCACGTAGGCAGAAACAGGAAAC 62°C 230 R: GGCACGTAGGCAGAATAAGC 7 203 R: GGAGAGGGAGGCCTGAGAAAC 60°C 171 BS F: GGAGAGGGAGGCCTGAGAAAAC 60°C 171		R: GTTACAGAACCACACTCGGA		
R: CCCCAGGGTGAGCCCCACAT 60°C 376 c-Kit F: CCTGGGATTTTCCTGCGTT 60°C 376 R: ATTGGTCACTTCTGGGTCTG F: GAC TGC GGC TIT TCT CCT ACC 55°C 418 R: TTT GGC GCT GTT CCT TTG AT 7 7 PF transition markers (Human) Amh F: CACCTGGAGGAAGTGACCTG 60°C 202 R: CCCCCGCTAACACCAGGTAG 60°C 202 R: CCACCGCTAACACCAGGTAG 60°C 202 R: ACCAGGTAGTGGAGTGACCTG 60°C 202 R: CCACCGCTAACACCAGGTAG 60°C 202 R: CCACCGCTAACACCAGGTAG 60°C 202 R: CCACGGTAGGGGGTGTCTCG 60°C 201 R: ACCAGGTAGTGAGCAGGTAACAGGAAT 65°C 291 R: TGCACACACATTTGACAGCAGGAGG 291 201 R: TGCACACACATTTGACCAGGAAGC 230 201 R: GGCACGTAGGCAGAATAAGC 202 230 Housekeeping gene (Human) 171 185 F: GGAGAGGGAGCCTGAGAAAC	Oct-4 (marmoset)	F: CCCCTGGTGCTGTGAAGCTGG	64°C	124
c-Kit F: CCTGGGATTTTCTCTGCGTT 60°C 376 R: ATTGGTCACTTCTGGGTCTG R: ATTGGTCACTTCTGGGTCTG 418 Vasa F: GAC TGC GGC TTT TCT CCT ACC 55°C 418 R: TTT GGC GCT GTT CCT TTG AT 7 7 PF transition markers (Human) Amh F: CACCTGGAGGAAGTGACCTG 60°C 202 R: CCACCGCTAACACCAGGTAG 60°C 202 R: CCACCGCTAACACCAGGTAG 60°C 202 R: CCACCGGCTAACACCAGGTAG 64°C 190 R: ACCAGGTAGTGGGTGTCTCG 7 7 Gdf-9 F: CTCCTGGAGACCAGGTAACAGGAAT 65°C 291 R: TGCACACACATTTGACAGGAAGT 65°C 230 R: GGCACGTAGGCAGAATAAGC 62°C 230 R: GGCACGTAGGCAGAATAAGC 60°C 171 185 F: GGAGAGGGAGCCTGAGAAAC 60°C 171		R: CCCCAGGGTGAGCCCCACAT		
R: ATTGGTCACTTCTGGGTCTG 55°C 418 Vasa F: GAC TGC GGC TIT TCT CCT ACC 55°C 418 R: TIT GGC GCT GTT CCT TIG AT 7 7 PF transition markers (Human) Amh F: CACCTGGAGGAAGTGACCTG 60°C 202 R: CCACCGCTAACACCAGGTAG 60°C 190 R: CCACGGCTAACACCAGGTAG 64°C 190 R: ACCAGGTAGTGGGTGTCTCG 7 7 Gdf-9 F: CTCCTGGAGACCAGGTAACAGGAAT 65°C 291 R: TGCACACACATTTGACAGCAGGAG 7 230 R: GCACCGTAGGCAGATAAGC 62°C 230 R: GCACGTAGGCAGAATAAGC 71 71 Housekeeping gene (Human)	c-Kit	F: CCTGGGATTTTCTCTGCGTT	60°C	376
Vasa F: GAC TGC GGC TTT TCT CCT ACC 55°C 418 R: TTT GGC GCT GTT CCT TTG AT 418 418 418 418 418 418 418 418 </td <td>R: ATTGGTCACTTCTGGGTCTG</td> <td></td> <td></td>		R: ATTGGTCACTTCTGGGTCTG		
R: TTT GGC GCT GTT CCT TTG AT PF transition markers (Human) Amh F: CACCTGGAGGAAGTGACCTG 60°C 202 R: CCACCGCTAACACCAGGTAG 202 Amh (marmoset) F: ACCTGGAGGAAGTGACATGG 64°C 190 R: ACCAGGTAGTGGGTGTCTCG 65°C 291 R: TGCACACACATTTGACAGCAAGGA 65°C 291 R: TGCACACACATTTGACAGCAAGG 230 230 R: GGCACGTAGGCAGAAATAAGC 110 230 Housekeeping gene (Human) 18S F: GGAGAGGGAGCCTGAGAAAC 60°C 171	Vasa	F: GAC TGC GGC TTT TCT CCT ACC	55°C	418
PF transition markers (Human) Amh F: CACCTGGAGGAAGTGACCTG 60°C 202 R: CCACCGCTAACACCCAGGTAG 60°C 202 Amh (marmoset) F: ACCTGGAGGAAGTGACATGG 64°C 190 R: ACCAGGTAGTGGGTGTCTCG 64°C 201 Gdf-9 F: CTCCTGGAGACCAGGTAACAGGAAT 65°C 291 R: TGCACACACATTTGACAGCAGAGG 7 230 R: GGCACGTAGGCAGAATAAGC 62°C 230 R: GGCACGTAGGCAGAATAAGC 71 Housekeeping gene (Human)		R: TTT GGC GCT GTT CCT TTG AT		
Amh F: CACCTGGAGGAAGTGACCTG 60°C 202 R: CCACCGCTAACACCAGGTAG 202 202 <t< td=""><td></td><td>PF transition mark</td><td>kers (Human)</td><td></td></t<>		PF transition mark	kers (Human)	
R: CCACCGCTAACACCCAGGTAG 190 Amh (marmoset) F: ACCTGGAGGAAGTGACATGG 64°C 190 R: ACCAGGTAGTGGGTGTCTCG 7 7 7 Gdf-9 F: CTCCTGGAGACCAGGTAACAGGAAT 65°C 291 R: TGCACACACATTTGACAGCAGAGG 7 230 R: GGCACGTAGGCAGAATAAGC 62°C 230 R: GGCACGTAGGCAGAATAAGC 7 7 Housekeeping gene (Human) 18S F: GGAGAGGGAGCCTGAGAAAC 60°C 171	Amh	F: CACCTGGAGGAAGTGACCTG	60°C	202
Amh (marmoset) F: ACCTGGAGGAAGTGACATGG 64°C 190 R: ACCAGGTAGTGGGTGTCTCG 7 7 Gdf-9 F: CTCCTGGAGACCAGGTAACAGGAAT 65°C 291 R: TGCACACACATTTGACAGCAGAGG 7 230 R: GGCACGTAGGCAGAATAAGC 62°C 230 R: GGCACGTAGGCAGAATAAGC 60°C 171 P: CTCCAATGCATCGAGAAAAC 60°C 171		R: CCACCGCTAACACCAGGTAG		
R: ACCAGGTAGTGGGTGTCTCG R: ACCAGGTAGTGGGTGTCTCG 291 Gdf-9 F: CTCCTGGAGACCAGGTAACAGGAAT 65°C 291 R: TGCACACACATTTGACAGCAGAGG 230 230 R: GGCACGTAGGCAGAATAAGC 62°C 230 R: GGCACGTAGGCAGAATAAGC 71 71 185 F: GGAGAGGGAGCCTGAGAAAC 60°C 171	Amh (marmoset)	F: ACCTGGAGGAAGTGACATGG	64°C	190
Gdf-9 F: CTCCTGGAGACCAGGTAACAGGAAT 65°C 291 R: TGCACACACTTTGACAGCAGAGG 200 230 Lhx8 F: CAAGCACAATTTGCTCAGGA 62°C 230 R: GGCACGTAGGCAGAATAAGC 1000000000000000000000000000000000000		R: ACCAGGTAGTGGGTGTCTCG		
R: TGCACACACATTTGACAGCAGAGG Lhx8 F: CAAGCACAATTTGCTCAGGA 62°C 230 R: GGCACGTAGGCAGAATAAGC	Gdf-9	F: CTCCTGGAGACCAGGTAACAGGAAT	65°C	291
Lhx8 F: CAAGCACAATTTGCTCAGGA 62°C 230 R: GGCACGTAGGCAGAATAAGC 7000000000000000000000000000000000000		R: TGCACACACATTTGACAGCAGAGG		
R: GGCACGTAGGCAGAATAAGC Housekeeping gene (Human) 185 F: GGAGAGGGAGCCTGAGAAAC 60°C 171 P: CCTCCAATCCTCCTTA 60°C 171	Lhx8	F: CAAGCACAATTTGCTCAGGA	62°C	230
Housekeeping gene (Human) 18S F: GGAGAGGGAGCCTGAGAAAC 60°C 171 P: CCTCCAATCCTCCTTA 60°C 171		R: GGCACGTAGGCAGAATAAGC		
185 F: GGAGAGGGAGCCTGAGAAAC 60°C 171		Housekeeping ge	ne (Human)	
	18S	F: GGAGAGGGAGCCTGAGAAAC	60°C	171
n. CEICLAAIGGAICEICGIIA		R: CCTCCAATGGATCCTCGTTA		

Table 2 List of primer details and PCR cycling conditions used in the study

Amh (granulosa cells), Gdf-9 and Lhx8 (oocyte specific).

were carried out in duplicates and the experiments were repeated thrice to determine the reproducibility of the results.

Results

Microscopic examination of ovarian cortical tissue

Cortical tissue pieces cultured on the membrane of cell culture inserts appeared dark under the inverted microscope (Figure 1A-C, F-H). However, few cells including RBCs interspersed with VSELs & OGSCs (ranging in size from 1-7 μ m) and larger epithelial cells (15-20 μ m) were observed to be released onto the culture insert membrane surface in both marmoset (Figure 1D) and human ovarian tissue culture (Figure 1E). OSE layer at high magnification was visible in human cortical tissue (Figure 1 F-H).

Regular monitoring of the released cells on the cell culture inserts showed that the epithelial cells attached to membrane surface and formed a monolayer. The stem cells (VSELs and OGSCs) appeared to grow in size and differentiate spontaneously into oocyte-like structures (Figure 1I-K) by the end of three weeks similar to ovary surface epithelium cultures reported earlier by various groups [18,19,29].

Histological analysis of ovarian cortical tissue *Marmoset*

Sections of the ovarian cortical tissue prior to culture demonstrated intact OSE layer and several intact PF (Figure 2). The OSE comprised of discontinuous and small cuboidal cells. Large numbers of PF were observed with a single layer of flattened granulosa cells (GC) surrounding the central oocyte. No signs of pycnotic nuclei, eosinophilia of ooplasm or clumping of the chromatin material were detected in the PF (Figure 2A), suggesting that the follicles were healthy.

The untreated control ovarian tissue on D3 in culture exhibited disorganization of the cortical stroma. The OSE layer appeared intact and continuous comprising of short cuboidal cells whereas the PF showed no initiation of growth (Figure 2B, C). The tissue sections of FSH treated cortical tissue revealed relatively better preserved



histology. The OSE appeared multilayered, exhibited hypertrophy and comprised of tall and columnar epithelial cells (Figure 2D). The granulosa cells in few follicles appeared cuboidal rather than flat, suggesting PF growth. Primary follicles with few intact PF were also observed (Figure 2E). The tissue harvested at D3 post treatment with bFGF appeared intact, similar to the FSH treated group. OSE appeared multi-layered with small spherical cells having high nucleocytoplasmic ratio and Hematoxylin stained dark nuclei were visible in some fields (inset,



Figure 2 Histology of marmoset ovarian cortical tissue: (**A**) OSE and PF were visualized in cortical tissue sections after Haematoxylin & Eosin staining prior to culture. (**B** & **C**) Three days culture in untreated control showed minimal OSE, few PF with pycnotic nuclei and disorganized cortex (**D** & **E**) Ovarian tissue sections after FSH treatment showed OSE proliferation and PF growth and transition to primary and secondary stage as evident by change in shape of the surrounding granulosa cells from flat and single layered in untreated control (**A**) to cuboidal and 2-3 layers after growth (**E**). (**F** & **G**) Ovarian tissue sections after bFGF treatment showed OSE proliferation and PF growth and transition to primary and secondary stage. Inset in F shows a darkly stained stem cell amongst OSE cells. Scale bar = 20 μm.

Figure 2F), which resembled the VSELs. Few PF, primary and secondary follicles were observed in the cortex (Figure 2G).

Human

In case of young human ovarian tissue, the OSE was discontinuous (data not shown) and relatively few intact PF were observed in the cortex before initiation of culture (Figure 3A). Some degree of transition of PF with flat GC to primary stage with cuboidal GC was observed in both FSH and bFGF treated groups, compared to untreated control sample which comprised majorly of PF (Figure 3B-D). The peri-menopausal ovarian sample had a well-defined OSE but was devoid of any follicles (Figure 3E). The OSE was unaffected after three days culture in the untreated group (Figure 3F), however it was multilayered and prominent after FSH treatment (Figure 3G).

Expression of pluripotent stem cells, germ cells and PF transition specific transcripts

Levels of transcripts for pluripotent stem cells (Oct-4A, Nanog), early germ cells/oocyte specific (Oct-4, c-Kit, Vasa) and to reflect PF transition into primary follicles (oocyte-specific Gdf-9 and Lhx8 and granulosa cell specific Amh) were analyzed. The transition specific markers were not studied in peri-menopausal tissue as this sample lacked PF. There was considerable biological variation in q-RTPCR results between samples but the basic trend remained similar while comparing data obtained in marmosets with that from human samples. Results were represented as fold change values over untreated control taken as 1 after normalizing with house-keeping gene (18S rRNA gene) and graphs were plotted on a logarithmic scale.

Pluripotent stem cell markers

Both Oct-4A and Nanog transcripts showed increased expression in marmoset and human cortical tissues treated with FSH and bFGF (Figure 4). Typically human sample showed an increase in Oct-4A transcripts in response to FSH treatment whereas Nanog mRNA was expressed to higher extent in bFGF treated group. FSH treatment in marmoset ovarian tissue showed higher expression of Nanog whereas bFGF treated group showed higher expression of Oct-4A transcripts. Typically young human ovary samples exhibited high fold change values for Nanog in both treated groups, whereas expression of both transcripts was comparable in the adult (perimenopausal) sample.

Early germ cell markers

A prominent and uniform up-regulation of germ cell specific markers was noticed after FSH and bFGF treatment in both marmoset and human samples compared to untreated control. Of all the three markers studied, Vasa showed highest fold change followed by c-Kit and Oct-4 in all the samples except young human sample treated with bFGF. Expression of early germ cell markers was most pronounced in young human sample. Although expression of c-Kit increased minimally with FSH treatment, the bFGF group did not exhibit any fluctuation in fold change value in marmoset sample. There was a consistent up-regulation of c-Kit in human samples in both treatment groups (Figure 4).

Markers to study PF growth and transition to primary follicle An increase in the expression of transition specific markers was noted in all the groups suggesting PF growth initiation (Figure 4).







pluripotent markers (Oct-4A and Nanog), early germ cell markers (Oct-4, c-Kit and Vasa) and PF growth initiation markers (oocyte specific Gdf-9, Lhx8 and granulosa cells specific Amh) were clearly up-regulated in response to bEGF and FSH treatment compared to untreated control (except Lhx-8 in marmoset after bEGF treatment). Values depicted are mean fold change in logarithmic scale obtained with respect to untreated controls taken as 1 and 18S rRNA as house-keeping gene. Marmoset data represents results obtained from three animals, whereas human data is representative of one young and one peri-menopausal ovary. *ND:Experiment not done*.

Discussion

The present study was undertaken to evaluate the effect of FSH and bFGF on PF transition from resting to growing stage during marmoset and human ovarian cortical tissue culture. Results revealed that in addition to the transition of resting PF to growing phase (as indicated by histological studies and increased expression of Gdf-9, Lhx-8 and Amh transcripts by q-RTPCR), proliferation of the OSE cells along with a release of stem cells onto the cell culture inserts was observed in response to FSH and bFGF. Also an increased expression of pluripotent stem cell (Oct-4A, Nanog) and germ cell (Oct-4, c-Kit, Vasa) specific markers was observed. A higher fold increase of stem cell markers was observed by q-RTPCR in the young human ovarian sample. Stem cells released on the inserts retained the ability to spontaneously differentiate into oocyte-like structures as reported earlier by our group [19]. Results of the present study demonstrate a direct role of FSH and bFGF on ovarian stem cells and PF growth initiation. These observations challenge the existing paradigm which suggests that FSH exerts indirect action on the germ cells via its receptors on granulosa cells and that initial follicular growth is gonadotropin independent [30].

Both FSH and bFGF induced increase in proliferation of OSE and also increased expression of pluripotent markers Oct-4A and Nanog in all the groups including the perimenopausal human ovarian sample devoid of PF. Expression of pluripotent stem cell markers Oct-4A and Nanog indirectly suggested the presence of pluripotent very small embryonic-like stem cells (VSELs) in the OSE as reported earlier by our group [19]. VSELs appear to increase in number after FSH or bFGF treatment. The increased expression of Oct-4A and Nanog as revealed by q-RTPCR, however may not reflect the true increase as large numbers of these stem cells were shed on to the membrane of cell culture insert, which were not processed for RNA extraction. Presence of stem cells in peri-menopausal ovary and their increase after FSH treatment suggests that stem cells persist and retain the ability to proliferate but menopause sets in due to a compromised microenvironment (somatic niche) which does not allow the stem cells to differentiate and

assemble into PF as suggested earlier by our group [19,20,31] and also others [32].

A similar increase in pluripotent stem cells and PF assembly in FSH analog treated mice has been reported by us [31]. It was intriguing to observe that FSH exerts action on the cortical tissue pieces comprising mainly of PF which are reported to be devoid of FSH receptors [8]. FSH action leading to follicular maturation is mediated via the granulosa cells of growing follicles which express FSH receptors [30,33]. Further studies are required to investigate the mechanism of FSH action on the ovarian stem cells.

Two distinct stem cell populations exist in the OSE including VSELs and their immediate descendants OGSCs [19]. We have earlier proposed that in the mammalian ovary, VSELs give rise to OGSCs just like the VSELs in the testis give rise to A_{dark} spermatogonial stem cells [19,20]. These immediate descendant 'progenitors' have cytoplasmic OCT-4B and divide rapidly whereas the VSELs express nuclear OCT-4A and are relatively quiescent. Presence of these two populations of stem cells in the gonads is in agreement with the recent reports demonstrating two distinct stem cell populations in various body tissues [34,35].

Available literature suggests that transition of PF into primary to secondary follicles occurs within 8-20 days of ovarian cortical tissue culture. We were indeed surprised to observe varying degree of damage to the PF in the histological sections. In view of this, survival of PF in extended cultures is rather intriguing. The poor morphology could be due to compromised culture condition or a fixation artifact in the present study. But we used culture conditions based on recent studies [14] and standard fixation protocols. This forced us to contemplate whether it is the pre-existing PF in cortical tissue or new follicles assembled from the ovarian stem cells which further grow into primary to secondary stage in the long-term (conducive environment of) culture conditions. We have earlier proposed that PF assemble in the OSE wherein the VSELs differentiate into oocytes and the epithelial cells undergo epithelial-mesenchymal transition to give rise to granulosa cells [19,20,31]. Garor et al [14] also observed an increased number of PF in bFGF treated ovarian cortical tissue culture (reported 301 follicles in the presence of 50 ng/ml of bFGF compared to 151 follicles in untreated control; presumably from similar number of cortical tissue pieces). However, it remains unclear whether the increase in number of follicles reported by them was due to better survival or *de novo* PF assembly from the stem cells in response to the treatment. More studies need to be undertaken in this direction. In the present study, an increased expression of transition associated markers for oocyte (Gdf-9 and Lhx-8) and granulosa cells (Amh) were observed after the treatment, suggestive of PF transition into primary follicles, in agreement with published literature [36-38].

Stimulation of pluripotent stem and early germ cell specific markers by bFGF was not surprising since bFGF receptors are reported to be present in the OSE [11]. Expression of above and PF transition specific markers were increased by several folds more after bFGF treatment compared to FSH, especially in young human ovarian tissue. Our results are in agreement with Garor et al. [14] who have also reported enhanced PF development in response to bFGF treatment during ovarian cortical tissue culture. It is likely that FSH and bFGF interact under normal circumstances in the ovary, to facilitate neo-oogenesis followed by PF assembly in mammalian ovary. FSH may exert its action via bFGF, as direct bFGF treatment leads to the enhanced effect. Especially the young human ovarian tissue responded more prominently to treatment with bFGF (>8 to 9 folds higher expression in bFGF compared to >2-3 folds in case of FSH group). However, more samples need to be studied before arriving at a final conclusion. Synergistic effect of FSH and bFGF in driving stem and germ cell development also requires further investigation.

The young human ovarian sample procured from autopsy, used in the present study, showed presence of few PF whereas the stem cells survived post death and exhibited increased stimulation by FSH and bFGF treatment. A better survival of stem cells compared to the PF could be because stem cells survive hypoxic conditions better in agreement with a recent study wherein viable stem cells were isolated seventeen days post death and they retained the ability to differentiate into skeletal muscles [39].

To conclude, culture of ovarian cortical tissue pieces is an excellent tool to study ovarian stem cell biology along with PF transition. Both FSH and bFGF stimulate the ovarian stem cells and probably aid in the assembly of stem cells as PF during extended cultures. It will be of great interest to study whether long-term culture of perimenopausal ovarian tissue can result in PF assembly from the stem cells in response to FSH and bFGF treatment. Results of the present study have translational potential for both oncotherapy and infertility.

Additional file

Additional file 1: Table S1. Details of markers used for characterization of pluripotent stem cells, germ cells and primordial follicle transition.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

SP carried out experimental work, data analysis, interpretation and manuscript drafting. DB was responsible for conceptualizing the contents of

the research article, planning experiments, providing scientific inputs, data interpretation and critical drafting of manuscript. DM performed ovariectomy of marmoset samples and reviewed the manuscript. AC and AJ were responsible for providing human ovarian tissue samples and reviewing the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We acknowledge the help of Dr Geetanjali Sachdeva and Dr Astrid Lobo for critical review of the manuscript. Research fellowship of Parte S from Lady Tata Memorial Trust, Mumbai and Council of Scientific & Industrial Research, New Delhi, India are acknowledged. This study was supported by grants from Indian Council of Medical Research, Government of India, New Delhi.

Author details

 ¹Stem Cell Biology Department, National Institute for Research in Reproductive Health (NIRRH), JM Street, Parel, Mumbai 400 012, India.
 ²Experimental Animal Facility, NIRRH, JM Street, Parel, Mumbai 400 012, India.
 ³Department of Obstetrics & Gynecology, Seth GS Medical College and King Edward Memorial Hospital, A Donde Marg, Parel, Mumbai 400 012, India.
 ⁴Department of Surgical Pathology, King Edward Memorial Hospital, A Donde Marg, Parel, Mumbai 400 012, India.

Received: 8 January 2013 Accepted: 22 March 2013 Published: 1 April 2013

References

- Brännström M, Milenkovic M: Advances in fertility preservation for female cancer survivors. Nat Med 2008, 14(11):1182–1184.
- Telfer EE, McLaughlin M, Ding C, Thong KJ: A two-step serum-free culture system supports development of human oocytes from primordial follicles in the presence of activin. *Hum Reprod* 2008, 23(5):1151–1158.
- Smitz J, Dolmans MM, Donnez J, Fortune JE, Hovatta O, Jewgenow K, Picton HM, Plancha C, Shea LD, Stouffer RL, Telfer EE, Woodruff TK, Zelinski MB: Current achievements and future research directions in ovarian tissue culture, in vitro follicle development and transplantation: implications for fertility preservation. *Hum Reprod Update* 2010, 16(4):395–414.
- Xu M, Fazleabas AT, Shikanov A, Jackson E, Barrett SL, Hirshfeld-Cytron J, Kiesewetter SE, Shea LD, Woodruff TK: *In vitro* oocyte maturation and preantral follicle culture from the luteal-phase baboon ovary produce mature oocytes. *Biol Reprod* 2011, 84(4):689–697.
- Hornick JE, Duncan FE, Shea LD, Woodruff TK: Isolated primate primordial follicles require a rigid physical environment to survive and grow *in vitro*. Hum Reprod 2012, 27(6):1801–1810.
- Wright CS, Hovatta O, Margara R, Trew G, Winston RM, Franks S, Hardy K: Effects of follicle-stimulating hormone and serum substitution on the invitro growth of human ovarian follicles. *Hum Rep* 1999, 14:1555–1562.
- O'Shaughnessy PJ, Dudley K, Rajapaksha WR: Expression of follicle stimulating hormone-receptor mRNA during gonadal development. Mol Cell Endocrinol 1996, 125(1–2):169–175.
- Oktay K, Briggs D, Gosden RGJ: Ontogeny of follicle-stimulating hormone receptor gene expression in isolated human ovarian follicles. *Clin Endocrinol Metab* 1997, 82(11):3748–3751.
- Silva JR, van den Hurk R, de Matos MH, dos Santos RR, Pessoa C, de Moraes MO, de Figueiredo JR: Influences of FSH and EGF on primordial follicles during *in vitro* culture of caprine ovarian cortical tissue. *Theriogenology* 2004, 61(9):1691–1704.
- Matos MH, Bruno JB, Rocha RM, Lima-Verde IB, Santos KD, Saraiva MV, Silva JR, Martins FS, Chaves RN, Báo SN, Figueiredo JR: *In vitro* development of primordial follicles after long-term culture of goat ovarian tissue. *Res Vet Sci* 2011, 90(3):404–411.
- van Wezel IL, Umapathysivam K, Tilley WD, Rodgers RJ: Immunohistochemical localization of basic fibroblast growth factor in bovine ovarian follicles. *Mol Cell Endocrinol* 1995, 115(2):133–140.
- Matos MH, Lima-Verde IB, Bruno JB, Lopes CA, Martins FS, Santos KD, Rocha RM, Silva JR, Báo SN, Figueiredo JR: Follicle stimulating hormone and fibroblast growth factor-2 interact and promote goat primordial follicle development in vitro. *Reprod Fertil Dev* 2007, 19(5):677–684.
- Quennell JH, Stanton JA, Hurst PR: Basic fibroblast growth factor expression in isolated small human ovarian follicles. *Mol Hum Reprod* 2004, 10(9):623–628.

- Garor R, Abir R, Erman A, Felz C, Nitke S, Fisch B: Effects of basic fibroblast growth factor on in vitro development of human ovarian primordial follicles. *Fertil Steril* 2009, 91(5 Suppl):1967–1975.
- Tang K, Yang WC, Li X, Wu CJ, Sang L, Yang LG: GDF-9 and bFGF enhance the effect of FSH on the survival, activation, and growth of cattle primordial follicles. *Anim Reprod Sci* 2012, 131(3–4):129–134.
- Burdette JE, Kurley SJ, Kilen SM, Mayo KE, Woodruff TK: Gonadotropininduced superovulation drives ovarian surface epithelia proliferation in CD1 mice. Endocrinol 2006, 147(5):2338–2345.
- 17. Bukovsky A, Svetlikova M, Caudle MR: **Oogenesis in cultures derived from** adult human ovaries. *Reprod Biol Endocrinol* 2005, **3**:17.
- Virant-Klun I, Stimpfel M, Skutella T: Ovarian pluripotent/multipotent stem cells and in vitro oogenesis in mammals. *Histol Histopathol* 2011, 26(8):1071–1082.
- Parte S, Bhartiya D, Telang J, Daithankar V, Salvi V, Zaveri K, Hinduja I: Detection, characterization, and spontaneous differentiation in vitro of very small embryonic-like putative stem cells in adult mammalian ovary. Stem Cells Dev 2011, 20(8):1451–1464.
- Bhartiya D, Sriraman K, Parte S: Stem cell interaction with somatic niche may hold the key to fertility restoration in cancer patients. Obstet Gynecol Int 2012, 921082. doi:10.1155/2012/921082. Epub 2012 Apr 2.
- 21. Pereira RC, Economides AN, Canalis E: Bone morphogenetic proteins induce gremlin, a protein that limits their activity inosteoblasts. *Endocrinol* 2000, **141**(12):4558–4563.
- Xu C, Rosler E, Jiang J, Lebkowski JS, Gold JD, O'Sullivan C, Delavan-Boorsma K, Mok M, Bronstein A, Carpenter MK: Basic fibroblast growth factor supports undifferentiated human embryonic stem cell growth without conditioned medium. *Stem Cells* 2005, 23(3):315–323.
- Liu Y, Song Z, Zhao Y, Qin H, Cai J, Zhang H, Yu T, Jiang S, Wang G, Ding M, Deng H: A novel chemical-defined medium with bFGF and N2B27 supplements supports undifferentiated growth in human embryonic stem cells. Biochem Biophys Res Commun 2006, 346(1):131–139.
- Levenstein ME, Ludwig TE, Xu RH, Llanas RA, VanDenHeuvel-Kramer K, Manning D, Thomson JA: Basic fibroblast growth factor support of human embryonic stem cell self-renewal. Stem Cells 2006, 24(3):568–574.
- Wandji SA, Srsen V, Nathanielsz PW, Eppig JJ, Fortune JE: Initiation of growth of baboon primordial follicles in vitro. Hum Reprod 1997, 12(9):1993–2001.
- 26. Fortune JE, Kito S, Wandji SA, Srsen V: Activation of bovine and baboon primordial follicles *in vitro*. *Theriogenology* 1998, **49**(2):441–449.
- 27. Muruvi W, Picton HM, Rodway RG, Joyce IM: *In vitro* growth and differentiation of primary follicles isolated from cryopreserved sheep ovarian tissue. *Anim Reprod Sci* 2009, **112**(1–2):36–50.
- McLaughlin M, Telfer EE: Oocyte development in bovine primordial follicles is promoted by activin and FSH within a two-step serum-free culture system. *Reproduction* 2010, 139(6):971–978.
- Bukovsky A: How can female germline stem cells contribute to the physiological neo-oogenesis in mammals and why menopause occurs? *Microsc Microanal* 2011, 17(4):498–505.
- 30. Edson MA, Nagaraja AK, Matzuk MM: The mammalian ovary from genesis to revelation. *Endocr Rev* 2009, **30**:624–712.
- Bhartiya D, Sriraman K, Gunjal P, Modak H: Gonadotropin treatment augments postnatal oogenesis and primordial follicle assembly in adult mouse ovaries? J Ovarian Res 2012, 5(1):32.
- Massasa E, Costa XS, Taylor HS: Failure of the stem cell niche rather than loss of oocyte stem cells in the aging ovary. Aging (Albany NY) 2010, 2(1):1–2.
- Yang P, Roy SK: A novel mechanism of FSH regulation of DNA synthesis in the granulosa cells of hamster preantral follicles: involvement of a protein kinase C-mediated MAP kinase 3/1 self-activation loop. *Biol Reprod* 2006, 75(1):149–157.
- 34. Li L, Clevers H: Coexistence of quiescent and active adult stem cells in mammals. *Science* 2010, **327**(5965):542–545.
- De Rosa L, De Luca M: Cell biology: dormant and restless skin stem cells. Nature 2012, 489(7415):215–217.
- 36. Visser JA, de Jong FH, Laven JS, Themmen AP: Anti-Müllerian hormone: a new marker for ovarian function. *Reproduction* 2006, 131(1):1–9.
- Sadeu JC, Adriaenssens T, Smitz J: Expression of growth differentiation factor 9, bone morphogenetic protein 15, and anti-Müllerian hormone in cultured mouse primary follicles. *Reproduction* 2008, 136(2):195–203.

- Zhang LJ, Pan B, Chen B, Zhang XF, Liang GJ, Feng YN, Wang LQ, Ma JM, Li L, Shen W: Expression and epigenetic dynamics of transcription regulator Lhx8 during mouse oogenesis. *Gene* 2012, 506(1):1–9.
- Latil M, Rocheteau P, Châtre L, Sanulli S, Mémet S, Ricchetti M, Tajbakhsh S, Chrétien F: Skeletal muscle stem cells adopt a dormant cell state post mortem and retain regenerative capacity. Nat Commun 2012, 3:903.

doi:10.1186/1757-2215-6-20

Cite this article as: Parte *et al.*: **Stimulation of ovarian stem cells by** follicle stimulating hormone and basic fibroblast growth factor during cortical tissue culture. *Journal of Ovarian Research* 2013 **6**:20.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

BioMed Central

(

Submit your manuscript at www.biomedcentral.com/submit